HPV Testing and Pap Test Market Size Worth $7.1 billion by 2027

According to a new report Global HPV Testing And Pap Test Market, published by KBV research, The Global HPV Testing And Pap Test Market size is expected to reach $7.1 billion by 2027, rising at a market growth of 33.5% CAGR during the forecast period.

The HPV testing segment would witness a major growth rate throughout the forecast years. Factors such as the commercialization of novel testing techniques and the rising number of government initiatives and suggestions to utilize more effective HPV screenings are responsible for the growth of the segment. In July 2018, the Society of Obstetricians and Gynecologists of Canada reported that the Pap test should be substituted by tests that can identify high-risk HPVs.

The vaginal cancer screening segment would showcase a significant growth rate throughout the forecast years. The demand for effective screening tests has been fueled by the growing cases and high mortality rates of vaginal cancer. As per the 2018 study by the American Cancer Society, approximately 1 in every 1,100 women is prone to develop vaginal cancer. In 2018, 5,350 women were identified with vaginal cancer in the U.S. The number of deaths associated with vaginal cancer in the U.S. was 1,430 in the same year.

The services segment would be the fastest-growing segment during the forecast years. This is due to the launch of self and at-home HPV screening solutions to enhance the screening rates of cervical cancer in the major markets. In January 2019, Nurx, a U.S.-based telemedicine company, launched its Home HPV Screening test, which allows women to recognize their risk affordably and comfortably for cervical cancer from home in the U.S.

In the Asia Pacific, the HPV testing and Pap tests would showcase promising growth rates throughout the forecast years. High occurrences of HPV and cervical cancer in the major countries of the regions such as Japan, India, and China are responsible for this massive growth. Moreover, the growth of the regional market would be propelled by the constant technological developments in the Asia-Pacific region.

Full Report: https://www.kbvresearch.com/hpv-testing-and-pap-test-market/

The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Abbott Laboratories, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific, Inc., Becton, Dickinson and Company, Hologic, Inc., Quest Diagnostics, Incorporated, Seegene, Inc., Arbor Vita Corporation, Femasys, Inc., and Qiagen N.V.

Global HPV Testing and Pap Test Market Segmentation

By Type

• Pap Test
• HPV Testing

By Application

• Cervical Cancer Screening,
• Vaginal Cancer Screening

By Product

• Consumables
• Instruments,
• Services

By End Use

• Hospitals & Clinics
• Laboratories
• Other End Users

By Geography

• North America
  • US
  • Canada
  • Mexico
  • Rest of North America
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
• LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Companies Profiled

• Abbott Laboratories
• F. Hoffmann-La Roche Ltd.
• Thermo Fisher Scientific, Inc.
• Becton, Dickinson and Company
• Hologic, Inc.
• Quest Diagnostics, Incorporated
• Seegene, Inc.
• Arbor Vita Corporation
• Femasys, Inc.
• Qiagen N.V.

Unique Offerings from KBV Research

• Exhaustive coverage
• The highest number of market tables and figures
• Subscription-based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free

HPV Testing and Pap Test Market Related Reports:

North America Market

Europe Market

Asia Pacific Market

LAMEA Market